At 12 months, however, a statistically significantly higher complete response rate was reported in the benralizumab arm vs the mepolizumab arm (48.1% vs 32.4%, respectively; P =.005).

TUESDAY, Dec. 10, 2024 (HealthDay News) -- Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a ...

Benralizumab, marketed by Astrazeneca (AZN), targets a specific type of white blood cells, called eosinophils, which is responsible for inflammation and damage in the lungs.

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used as a repeat treatment for severe asthma at a ...

A new treatment for asthma attacks is being described as “game-changing” by the London scientists who created it. The drug, which is called benralizumab, is the first new treatment for asthma attacks ...

Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. The drug, which is delivered by an injection, helps to treat flare-ups of the ...

The drug, which is called benralizumab, is the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. A trial has shown that using the drug can cut ...

A new treatment for asthma attacks is being described as “game-changing” by the London scientists who created it.. The drug, which is called benralizumab, is the first new treatment for asthma attacks ...

The drug, which is called benralizumab, is the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years. A trial has shown that using the drug can cut ...

Benralizumab is a much-needed treatment option, with data showing that not only is remission an achievable goal for EGPA patients, but benralizumab can also help patients taper off steroid therapy.” ...